An interesting announcement. Whilst pleasing to see significant revenue growth via this arm, month on month, it's a bit concerning kava sales growth has been as muted as it is.
Infrastructure/foundations seem to now be reasonably well set, but it would've been nice if this occurred a few years earlier. Perhaps the funds from the iTaukei board and Chemist Warehouse were the necessary impetus.
Either way, the apparent contract sales out of China seem to be completely nonsense. Really disappointing for many holders, but there remains the faintest of lights at the end of the tunnel, particularly with the Calmer Co/Danodan purchase.
FIJ Price at posting:
3.0¢ Sentiment: Buy Disclosure: Held
